Vegetation maps are fundamental for regional-scale ecological research. However, information is often not sufficiently up to date for such research. The Loess Plateau is a key area for vegetation restoration projects ...Vegetation maps are fundamental for regional-scale ecological research. However, information is often not sufficiently up to date for such research. The Loess Plateau is a key area for vegetation restoration projects and a suitable area for regional ecological research. To carry out regional vegetation mapping based on the principles of hierarchical classification, object-oriented methods, visual interpretation, and accuracy assessment, this study integrated land cover, high-resolution remote sensing images, background environmental data, bioclimate zoning data, and field survey data from the Loess Plateau. To further clarify the implications of vegetation mapping, we compared the deviation of the 2015 vegetation map of the Loess Plateau(VMLP) and the widely used vegetation map of China(VMC)(1 : 1 000 000) for the expressed vegetation information and the evaluation of ecosystem services. The results indicated that 1) the vegetation of the Loess Plateau could be divided into 9 vegetation type groups and 18 vegetation types with classification accuracies of 87.76% and 83.97%, respectively;2) the distribution of vegetation had obvious zonal regularity;3) a deviation of 29.56 × 10^4 km^2 occurred when the vegetation coverage area was quantified with the VMC;4) the vegetation classification accuracy affected the ecosystem service assessment, the total water yield of the Loess Plateau calculated by the VMC and other required parameters was overestimated by 2.2 × 10^6 mm in 2015. Because vegetation mapping is a basic and important activity, that requires greater attention, this study provides supporting data for subsequent multivariate vegetation mapping and vegetation management for conservation and restoration.展开更多
OBJECTIVE:To evaluate the efficacy and safety of Shengmai Yin(生脉饮,SMY)on visual analogue scale(VAS)for cardiopulmonary symptoms in coronavirus disease 2019(COVID-19)convalescent patients.METHODS:In this randomized,...OBJECTIVE:To evaluate the efficacy and safety of Shengmai Yin(生脉饮,SMY)on visual analogue scale(VAS)for cardiopulmonary symptoms in coronavirus disease 2019(COVID-19)convalescent patients.METHODS:In this randomized,double blind and multicenter controlled trial,a total of 200 COVID-19 convalescent patients who with cardiopulmonary symptoms were enrolled from three medical centers in Hubei,China.These patients were randomized divided into trial group and the control group,100 patients in each one,SMY and its placebo were applied to respectively,for two weeks.VAS of clinical symptoms included shortness of breath,hidrosis,chest distress,palpitation,and dry cough was performed at 0,1,2 weeks.Decrease in VAS of 30%or more was defined as effective,and a reduction in VAS of 0 was defined as curative.RESULTS:A total of 192 completed the study.The VAS of TCM symptoms showed there was no difference in baseline between the two groups.The VAS in both groups was down-regulated,and there was no significant difference in VAS and cure rates at the first and second week between the two groups.There was no significant difference in breath,hidrosis,palpitation,and dry cough between the two groups but SMY treatment for two weeks has remarkable therapeutic effects in chest distress than placebo.CONCLUSIONS:SMY could effectively ameliorate the symptoms of chest distress,and improve the quality of life of the COVID-19 convalescent patients.展开更多
OBJECTIVE:To evaluate the effectiveness and safety of Jinshuibao capsules(金水宝胶囊),a Traditional Chinese Medicine(TCM),in the treatment of residual cardiopulmonary symptoms in convalescent corona virus disease 2019...OBJECTIVE:To evaluate the effectiveness and safety of Jinshuibao capsules(金水宝胶囊),a Traditional Chinese Medicine(TCM),in the treatment of residual cardiopulmonary symptoms in convalescent corona virus disease 2019(COVID-19)patients.METHODS:A total of 200 participants with COVID-19 in convalescence phase were randomly assigned into two groups at a 1:1 ratio in this multicenter randomized,double-blind,placebo-controlled trial.One group received Jinshuibao capsules,and the other received placebo.The patients were followed up at one and two weeks of treatment.Five symptoms(dry cough,shortness of breath,sweating,chest tightness and palpitation)improvement rates and full recovery rates were compared.RESULTS:All baseline characteristics were comparable between the two groups.After two weeks of treatment,symptom improvement rates for dry cough(74.00%vs 50.00%,P=0.015),shortness of breath(78.95%vs 46.15%,P<0.001),sweating(80.00%vs 57.75%,P=0.004),chest tightness(87.06%vs 60.47%,P<0.001)and palpitation(82.50%vs 64.56%,P=0.010)were significantly higher in the Jinshuibao group compared with the control group.Meanwhile,Jinshuibao capsules treatment also displayed more satisfactory full recovery rates of all five symptoms(dry cough 58.00%vs 19.57%,shortness of breath 18.95%vs 7.69%,sweating 36.00%vs 19.72%,chest tightness 32.94%vs 13.95%,and palpitation 48.75%vs 29.11%)in participants with COVID-19 in convalescence phase compared with the control group(P<0.05).No severe adverse events were reported in either group.CONCLUSIONS:Jinshuibao capsules have the potential to improve residual cardiopulmonary symptoms in convalescent COVID-19 patients,with few adverse events.展开更多
OBJECTIVE:To evaluate the effectiveness and safety of Xiangsha Liujun pills(香砂六君丸) on the decreased digestive function in patients in the recovery phase of the Coronavirus disease 2019(COVID-19).METHODS:A randomi...OBJECTIVE:To evaluate the effectiveness and safety of Xiangsha Liujun pills(香砂六君丸) on the decreased digestive function in patients in the recovery phase of the Coronavirus disease 2019(COVID-19).METHODS:A randomized,double blind,placebo controlled clinical trial was conducted.A total of 200 COVID-19 patients in the recovery phase were included in our study in Ezhou Hospital of Traditional Chinese Medicine.Totally 200 subjects were randomly divided into a treatment group(Xiangsha Liujun pills) and a control group(placebo),with 100 in each group.Subjects took Xiangsha Liujun pills or placebo orally three times a day for two weeks.Three visits were scheduled at week 0(baseline),week 1(the middle of the intervention) and week 2(the end of the intervention) for each eligible patient.The total efficacy rates for improving the Traditional Chinese Medicine(TCM) symptoms(fatigue,poor appetite,abdominal distension and loose stools) and the disappearance rates of symptoms were observed and compared in the treatment and control groups.Adverse events were recorded during the study period.SAS 9.4 was used to analyze the data.RESULTS:A total of 200 patients were included in this study,among which 4 participants withdrew because the drugs did not work.Three patients were excluded for age.Before the treatment,there was no significant difference between the TCM symptoms scores of subjects.After 1 week of treatment,the full analysis set(FAS) showed that the efficacy rates for abdominal distension and loose stools in the treatment group were significantly higher than the control group(P < 0.05).There were no significant differences in the efficacy rates for fatigue and poor appetite between the two groups(P > 0.05).In addition,the disappearance rate of fatigue in the treatment group was significantly higher than the control group(P < 0.05);there were no significant differences between the two groups after treatment in the rates of poor appetite,abdominal distension,and loose stools(P > 0.05).After 2 weeks of treatment,the efficacy rates for fatigue,poor appetite,abdominal distension,and loose stools in the treatment group were significantly higher than the control group(P < 0.05).The disappearance rate of loose stools in the treatment group was significantly higher than the control group(P < 0.05).However,there were no significant differences in the disappearance rates of fatigue,poor appetite,and abdominal distension between the two groups(P > 0.05).No severe adverse events were reported by subjects during the study.CONCLUSIONS:This clinical study confirmed that Xiangsha Liujun pills can effectively improve the symptoms related to the decreased digestive function in COVID-19 convalescent patients.展开更多
OBJECTIVE:To study the efficacy of Xiaoyao capsule(逍遥丸)in improving the clinical symptoms of sleep and mood disorders during recovery from coronavirus disease 2019(COVID-19).METHODS:The study cohort comprised 200 p...OBJECTIVE:To study the efficacy of Xiaoyao capsule(逍遥丸)in improving the clinical symptoms of sleep and mood disorders during recovery from coronavirus disease 2019(COVID-19).METHODS:The study cohort comprised 200 patients with sleep and mood disorders during recovery from COVID-19.Patients were randomized into the control group and the experimental group in a 1:1 ratio by blocked randomization.The patients received either Xiaoyao capsule(experimental group)or a placebo Xiaoyao capsule(control group)for 2 weeks.The improvements in the Traditional Chinese Medicine(TCM)syndrome scales,total effective rates,and disappearance rates of irritability,anxiety,and poor sleep were compared between the two groups.RESULTS:The TCM syndrome pattern scales,total effective rates,and disappearance rates of irritability,anxiety,and poor sleep did not significantly differ between the experimental group versus the control group in the full analysis set and the per protocol set after 1 and 2 weeks of treatment(P>0.05).CONCLUSIONS:Xiaoyao capsule do not significantly improve the clinical symptoms of sleep and mood disorders in patients in recovery from COVID-19.展开更多
基金Under the auspices of National Key Research and Development Program of China(No.2016YFC0501601)Key Science and Technology Project of Yan’an Municipality(No.2016CGZH-14-03)。
文摘Vegetation maps are fundamental for regional-scale ecological research. However, information is often not sufficiently up to date for such research. The Loess Plateau is a key area for vegetation restoration projects and a suitable area for regional ecological research. To carry out regional vegetation mapping based on the principles of hierarchical classification, object-oriented methods, visual interpretation, and accuracy assessment, this study integrated land cover, high-resolution remote sensing images, background environmental data, bioclimate zoning data, and field survey data from the Loess Plateau. To further clarify the implications of vegetation mapping, we compared the deviation of the 2015 vegetation map of the Loess Plateau(VMLP) and the widely used vegetation map of China(VMC)(1 : 1 000 000) for the expressed vegetation information and the evaluation of ecosystem services. The results indicated that 1) the vegetation of the Loess Plateau could be divided into 9 vegetation type groups and 18 vegetation types with classification accuracies of 87.76% and 83.97%, respectively;2) the distribution of vegetation had obvious zonal regularity;3) a deviation of 29.56 × 10^4 km^2 occurred when the vegetation coverage area was quantified with the VMC;4) the vegetation classification accuracy affected the ecosystem service assessment, the total water yield of the Loess Plateau calculated by the VMC and other required parameters was overestimated by 2.2 × 10^6 mm in 2015. Because vegetation mapping is a basic and important activity, that requires greater attention, this study provides supporting data for subsequent multivariate vegetation mapping and vegetation management for conservation and restoration.
基金Supported by Randomized,Double-blind,Placebo-controlled,Multicenter Clinical Study to Improve Symptoms Associated with Pulmonary Heart Function during Recovery from COVID-19(II)(No.2020ZYLCYJ08-4)。
文摘OBJECTIVE:To evaluate the efficacy and safety of Shengmai Yin(生脉饮,SMY)on visual analogue scale(VAS)for cardiopulmonary symptoms in coronavirus disease 2019(COVID-19)convalescent patients.METHODS:In this randomized,double blind and multicenter controlled trial,a total of 200 COVID-19 convalescent patients who with cardiopulmonary symptoms were enrolled from three medical centers in Hubei,China.These patients were randomized divided into trial group and the control group,100 patients in each one,SMY and its placebo were applied to respectively,for two weeks.VAS of clinical symptoms included shortness of breath,hidrosis,chest distress,palpitation,and dry cough was performed at 0,1,2 weeks.Decrease in VAS of 30%or more was defined as effective,and a reduction in VAS of 0 was defined as curative.RESULTS:A total of 192 completed the study.The VAS of TCM symptoms showed there was no difference in baseline between the two groups.The VAS in both groups was down-regulated,and there was no significant difference in VAS and cure rates at the first and second week between the two groups.There was no significant difference in breath,hidrosis,palpitation,and dry cough between the two groups but SMY treatment for two weeks has remarkable therapeutic effects in chest distress than placebo.CONCLUSIONS:SMY could effectively ameliorate the symptoms of chest distress,and improve the quality of life of the COVID-19 convalescent patients.
基金Supported by National Administration of Traditional Chinese Medicine:a Randomized,Double Blinded,Controlled,Multicenter Clinical Trial to Improve the Symptoms of Pulmonary and Cardiac Function During the Convalescence of COVID-19(2020ZYLCYJ08-3)the State Administration of Traditional Chinese Medicine Special Project of Chinese Medicine Emergency Response to New Coronavirus Pneumonia(2020ZYLCYJ04-1)National Key R&D Program(2020YFC0845000)。
文摘OBJECTIVE:To evaluate the effectiveness and safety of Jinshuibao capsules(金水宝胶囊),a Traditional Chinese Medicine(TCM),in the treatment of residual cardiopulmonary symptoms in convalescent corona virus disease 2019(COVID-19)patients.METHODS:A total of 200 participants with COVID-19 in convalescence phase were randomly assigned into two groups at a 1:1 ratio in this multicenter randomized,double-blind,placebo-controlled trial.One group received Jinshuibao capsules,and the other received placebo.The patients were followed up at one and two weeks of treatment.Five symptoms(dry cough,shortness of breath,sweating,chest tightness and palpitation)improvement rates and full recovery rates were compared.RESULTS:All baseline characteristics were comparable between the two groups.After two weeks of treatment,symptom improvement rates for dry cough(74.00%vs 50.00%,P=0.015),shortness of breath(78.95%vs 46.15%,P<0.001),sweating(80.00%vs 57.75%,P=0.004),chest tightness(87.06%vs 60.47%,P<0.001)and palpitation(82.50%vs 64.56%,P=0.010)were significantly higher in the Jinshuibao group compared with the control group.Meanwhile,Jinshuibao capsules treatment also displayed more satisfactory full recovery rates of all five symptoms(dry cough 58.00%vs 19.57%,shortness of breath 18.95%vs 7.69%,sweating 36.00%vs 19.72%,chest tightness 32.94%vs 13.95%,and palpitation 48.75%vs 29.11%)in participants with COVID-19 in convalescence phase compared with the control group(P<0.05).No severe adverse events were reported in either group.CONCLUSIONS:Jinshuibao capsules have the potential to improve residual cardiopulmonary symptoms in convalescent COVID-19 patients,with few adverse events.
基金Supported by Special Fund of the Technology Division of State Administration of Traditional Chinese Medicine:a Randomized,Double Blinded,Controlled Clinical Trial to Improve the Symptoms of Decreased Digestive Function During the Convalescence of COVID-19(No.2020ZYLCYJ08-5)。
文摘OBJECTIVE:To evaluate the effectiveness and safety of Xiangsha Liujun pills(香砂六君丸) on the decreased digestive function in patients in the recovery phase of the Coronavirus disease 2019(COVID-19).METHODS:A randomized,double blind,placebo controlled clinical trial was conducted.A total of 200 COVID-19 patients in the recovery phase were included in our study in Ezhou Hospital of Traditional Chinese Medicine.Totally 200 subjects were randomly divided into a treatment group(Xiangsha Liujun pills) and a control group(placebo),with 100 in each group.Subjects took Xiangsha Liujun pills or placebo orally three times a day for two weeks.Three visits were scheduled at week 0(baseline),week 1(the middle of the intervention) and week 2(the end of the intervention) for each eligible patient.The total efficacy rates for improving the Traditional Chinese Medicine(TCM) symptoms(fatigue,poor appetite,abdominal distension and loose stools) and the disappearance rates of symptoms were observed and compared in the treatment and control groups.Adverse events were recorded during the study period.SAS 9.4 was used to analyze the data.RESULTS:A total of 200 patients were included in this study,among which 4 participants withdrew because the drugs did not work.Three patients were excluded for age.Before the treatment,there was no significant difference between the TCM symptoms scores of subjects.After 1 week of treatment,the full analysis set(FAS) showed that the efficacy rates for abdominal distension and loose stools in the treatment group were significantly higher than the control group(P < 0.05).There were no significant differences in the efficacy rates for fatigue and poor appetite between the two groups(P > 0.05).In addition,the disappearance rate of fatigue in the treatment group was significantly higher than the control group(P < 0.05);there were no significant differences between the two groups after treatment in the rates of poor appetite,abdominal distension,and loose stools(P > 0.05).After 2 weeks of treatment,the efficacy rates for fatigue,poor appetite,abdominal distension,and loose stools in the treatment group were significantly higher than the control group(P < 0.05).The disappearance rate of loose stools in the treatment group was significantly higher than the control group(P < 0.05).However,there were no significant differences in the disappearance rates of fatigue,poor appetite,and abdominal distension between the two groups(P > 0.05).No severe adverse events were reported by subjects during the study.CONCLUSIONS:This clinical study confirmed that Xiangsha Liujun pills can effectively improve the symptoms related to the decreased digestive function in COVID-19 convalescent patients.
文摘OBJECTIVE:To study the efficacy of Xiaoyao capsule(逍遥丸)in improving the clinical symptoms of sleep and mood disorders during recovery from coronavirus disease 2019(COVID-19).METHODS:The study cohort comprised 200 patients with sleep and mood disorders during recovery from COVID-19.Patients were randomized into the control group and the experimental group in a 1:1 ratio by blocked randomization.The patients received either Xiaoyao capsule(experimental group)or a placebo Xiaoyao capsule(control group)for 2 weeks.The improvements in the Traditional Chinese Medicine(TCM)syndrome scales,total effective rates,and disappearance rates of irritability,anxiety,and poor sleep were compared between the two groups.RESULTS:The TCM syndrome pattern scales,total effective rates,and disappearance rates of irritability,anxiety,and poor sleep did not significantly differ between the experimental group versus the control group in the full analysis set and the per protocol set after 1 and 2 weeks of treatment(P>0.05).CONCLUSIONS:Xiaoyao capsule do not significantly improve the clinical symptoms of sleep and mood disorders in patients in recovery from COVID-19.
